中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

53 records (took 0.025 seconds)

    Chitosan core matrix containing cells encapsulated in a thermoplastic semipermeable membrane
    1.
    发明授权
    Chitosan core matrix containing cells encapsulated in a thermoplastic semipermeable membrane 失效
    壳聚糖核心基质含有包封在热塑性半透膜中的细胞

    公开(公告)号：US6140089A

    公开(公告)日：2000-10-31

    申请号：US251004

    申请日：1999-02-16

    Applicant: Patrick Aebischer ,  Beth A. Zielinski

    Inventor： Patrick Aebischer ,  Beth A. Zielinski

    IPC: A61K35/12 ,  A61L27/20 ,  A61L27/38 ,  C12N5/077 ,  C12N5/0793 ,  C12N11/10 ,  C12N11/04 ,  C12N5/00

    CPC classification number: C12N5/0012 ,  A61L27/20 ,  A61L27/38 ,  A61L27/3804 ,  C12N5/0618 ,  C12N5/0619 ,  A61K2035/128 ,  A61K35/12

    Abstract: Encapsulated viable cells for implanting are prepared having cells dispersed in a particulate, essentially non cross-linked chitosan core matrix that is enclosed within a semipermeable membrane. The cells are entrapped between chitosan particles of the core matrix and there is essentially no interfacial cross-linking between the core matrix and the membrane. The core matrix provides a physical support for the cells such that the cells are evenly dispersed throughout the core matrix so as to allow their maintenance, growth, proliferation and differentiation. The encapsulated cells may be prepared by mixing viable cells with a solution of chitosan, encapsulating the resultant mixture in a thermoplastic semipermeable membrane, and causing the chitosan to precipitate such as by changing the pH to form the core matrix. Alternatively, the chitosan in solution is precipitated to form the core matrix containing cells, and the core matrix is encapsulated in a semipermeable membrane. Cells encapsulated include neurosecretory cell lines, .beta.-cell-derived cells lines, fibroblasts, myocytes and glial cells.

    Abstract translation: 制备用于植入的包封的活细胞，其具有分散在颗粒状基本上非交联壳聚糖核心基质中的细胞，其被包封在半透膜内。 细胞被截留在核心基质的壳聚糖颗粒之间，并且核心基质和膜之间基本上没有界面交联。 核心基质为细胞提供物理支持，使得细胞均匀地分散在整个核心基质中，以便使其维持，生长，增殖和分化。 包封的细胞可以通过将活细胞与壳聚糖溶液混合，将所得混合物包封在热塑性半透膜中并使壳聚糖沉淀，例如通过改变pH以形成核心基质来制备。 或者，将溶液中的壳聚糖沉淀以形成含核心基质的细胞，并将核心基质包封在半透膜中。 包封的细胞包括神经分泌细胞系，β-细胞来源的细胞系，成纤维细胞，肌细胞和神经胶质细胞。

    Particulate non cross-linked chitosan core matrices for encapsulated cells
    2.
    发明授权
    Particulate non cross-linked chitosan core matrices for encapsulated cells 失效
    用于封装细胞的颗粒非交联壳聚糖核心基质

    公开(公告)号：US5871985A

    公开(公告)日：1999-02-16

    申请号：US294149

    申请日：1994-08-22

    Applicant: Patrick Aebischer ,  Beth A. Zielinski

    Inventor： Patrick Aebischer ,  Beth A. Zielinski

    IPC: A61K35/12 ,  A61L27/20 ,  A61L27/38 ,  C12N5/077 ,  C12N5/0793 ,  C12N11/10 ,  C12N11/04 ,  C12N5/00

    CPC classification number: C12N5/0012 ,  A61L27/20 ,  A61L27/38 ,  A61L27/3804 ,  C12N5/0618 ,  C12N5/0619 ,  A61K2035/128 ,  A61K35/12

    Abstract: Vehicles containing cells for implanting in the tissue of an individual are prepared having cells dispersed in a particulate, essentially non cross-linked chitosan core matrix that is enclosed within a semipermeable membrane. The cells are entrapped between chitosan particles of the core matrix and there is essentially no interfacial cross-linking between the core matrix and the membrane. The core matrix provides a physical support for viable cells within the vehicle such that the cells are evenly dispersed throughout the core matrix so as to allow their maintenance, growth, proliferation and differentiation. The vehicle can be prepared by mixing viable cells with a solution of chitosan, encapsulating the resultant mixture in a semipermeable membrane and causing the chitosan to precipitate such as by changing the pH to form the core matrix. Alternatively, the chitosan is precipitated to form the core matrix containing cells and then the core matrix is encapsulated in a semipermeable membrane. Cells within the core matrix may be neurosecretory cell lines, .beta.-cell-derived cells lines, fibroblasts, myocytes and glial cells.

    Abstract translation: 制备含有用于植入个体组织的细胞的载体，其具有分散在颗粒状基本上非交联壳聚糖核心基质中的细胞，所述壳聚糖核心基质被包封在半透膜内。 细胞被截留在核心基质的壳聚糖颗粒之间，并且核心基质和膜之间基本上没有界面交联。 核心基质为载体内的活细胞提供物理支持，使得细胞均匀分散在整个核心基质中，以使其维持，生长，增殖和分化。 载体可以通过将活细胞与壳聚糖溶液混合来制备，将所得混合物包封在半透膜中并使壳聚糖沉淀，例如通过改变pH以形成核心基质。 或者，将壳聚糖沉淀形成含核心基质的细胞，然后将核心基质包封在半透膜中。 核心基质内的细胞可以是神经分泌细胞系，β-细胞来源的细胞系，成纤维细胞，肌细胞和神经胶质细胞。

    Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases
    4.
    发明授权
    Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases 失效
    慢病毒介导的神经变性疾病生长因子基因治疗

    公开(公告)号：US06800281B2

    公开(公告)日：2004-10-05

    申请号：US10008610

    申请日：2001-11-08

    Applicant: Patrick Aebischer ,  Susan Mary Kingsman ,  Stuart Naylor ,  Nicholas Mazarakis

    Inventor： Patrick Aebischer ,  Susan Mary Kingsman ,  Stuart Naylor ,  Nicholas Mazarakis

    IPC: A61K4800

    CPC classification number: C12N15/86 ,  A61K48/00 ,  C07K14/4756 ,  C12N2740/15043

    Abstract: Disclosed and claimed are methods for treating or preventing neurodegenerative diseases, conditions or maladies or symptoms or physiology associated therewith, such as treating or preventing Parkinson's disease or symptoms or physiology associated therewith such as motor deficits or nigrostriatal degeneration; or, for inducing nigrostriatal regeneration. Advantageously, the methods involve administering a lentiviral vector that expresses GDNF, such as human GDNF, or a variant, homolog, analog or derivative thereof.

    Abstract translation: 公开并要求保护的是用于治疗或预防神经变性疾病，病症或疾病或症状或与之相关的生理学的方法，例如治疗或预防帕金森病或与之相关的症状或生理学，例如运动缺陷或黑质纹状体变性; 或用于诱导黑质纹状体再生。 有利地，所述方法包括施用表达GDNF的慢病毒载体，例如人GDNF，或其变体，同系物，类似物或衍生物。

    Devices for neural signal transmission
    9.
    发明授权
    Devices for neural signal transmission 失效
    神经信号传输装置

    公开(公告)号：US4878913A

    公开(公告)日：1989-11-07

    申请号：US93371

    申请日：1987-09-04

    Applicant: Patrick Aebischer ,  Robert F. Valentini ,  Pierre M. Galletti

    Inventor： Patrick Aebischer ,  Robert F. Valentini ,  Pierre M. Galletti

    IPC: A61F2/72

    CPC classification number: A61F2/72

    Abstract: Devices and methods for transmitting neural signals from a proximal stump of a transected nerve to a prosthetic apparatus are disclosed employing microelectrodes, preferably conductive fiber networks, capable of sensing electrical signals from a nerve and transmitting such signals to a prosthetic apparatus; and a semipermeable guidance channel disposed about the microelectrodes. The channels include an opening adapted to receive the proximal stump of a transected nerve, such that the channel promotes the growth of the stump and the formation of an electrical connection between the transected nerve and the microelectrode.

    Pharmaceutical microencapsulation
    10.
    发明授权
    Pharmaceutical microencapsulation 失效
    药物微胶囊化

    公开(公告)号：US6080412A

    公开(公告)日：2000-06-27

    申请号：US162590

    申请日：1998-09-29

    Applicant: Olivier Jordan ,  Patrick Aebischer ,  Jean-Francois Clemence

    Inventor： Olivier Jordan ,  Patrick Aebischer ,  Jean-Francois Clemence

    IPC: A61K9/50 ,  A61K35/12 ,  A61L27/00 ,  A61L27/38 ,  C12N5/071 ,  C12N11/04 ,  C07K1/00

    CPC classification number: A61L27/3804 ,  A61K9/5026 ,  A61K9/5089 ,  C12N11/04 ,  C12N5/0677 ,  A61K2035/128

    Abstract: A method of producing a microencapsulated pharmaceutical formulation is disclosed comprising causing a dye to be attached to the surface of pharmaceutical particles or particle clusters and applying a source of radiant energy to the dye in the presence of a liquid polymeric or polymerisable material so as to cause the material to cross-link, producing a conformal layer of cross-linked polymer on the particulate surfaces. Preferably, the polymer provides an immuno-protective layer around the particles, while allowing therapeutic components to exit the microcapsules. Microencapsulated pharmaceutical formulations and their medical use are also disclosed, especially for the treatment of diabetes by encapsulating insulin secreting cells.

    Abstract translation: 公开了一种生产微胶囊化药物制剂的方法，其包括使染料附着在药物颗粒或颗粒簇的表面上，并在液体聚合或可聚合材料的存在下将辐射能源施加到染料上，从而引起 交联的材料，在颗粒表面上产生交联聚合物的共形层。 优选地，聚合物在颗粒周围提供免疫保护层，同时允许治疗成分离开微胶囊。 还公开了微囊化药物制剂及其医疗用途，特别是用于通过包封胰岛素分泌细胞治疗糖尿病。

Patent Agency Ranking